Updates are available Correction dated 2021-12-02
Click to view Correction: https://doi.org/10.1186/s13014-021-01941-z
-
Authors
Hanna, Catherine R. http://orcid.org/0000-0002-0907-7747
O’Cathail, Sean M. http://orcid.org/0000-0001-5574-9199
Graham, Janet S. http://orcid.org/0000-0002-2048-2698
Saunders, Mark
Samuel, Leslie http://orcid.org/0000-0002-8402-8670
Harrison, Mark
Devlin, Lynsey http://orcid.org/0000-0002-4047-0686
Edwards, Joanne
Gaya, Daniel R.
Kelly, Caroline A. http://orcid.org/0000-0002-5330-7888
Lewsley, Liz-Anne
Maka, Noori
Morrison, Paula
Dinnett, Louise
Dillon, Susan http://orcid.org/0000-0002-6676-1393
Gourlay, Jacqueline
Platt, Jonathan J.
Thomson, Fiona http://orcid.org/0000-0002-8987-5369
Adams, Richard A. http://orcid.org/0000-0003-3915-7243
Roxburgh, Campbell S. D. http://orcid.org/0000-0002-2649-6695
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04621370 at ClinicalTrials.govDocuments that mention this clinical trial
Durvalumab (MEDI 4736) in combination with extended neoadjuvant regimens in rectal cancer: a study protocol of a randomised phase II trial (PRIME-RT)
https://doi.org/10.1186/s13014-021-01888-1
-
Funding
Funding for this research was provided by:
Cancer Research UK (C61974/A2429)
- License Information
-
More Information
Article History
Received: 6 April 2021
Accepted: 16 August 2021
First Online: 26 August 2021
Change Date: 2 December 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s13014-021-01941-z
Declarations
:
: PRIME-RT was approved by the East of Scotland Research Ethics Service on 23rd October 2020 (reference 20/ES/0083) and by the MHRA on 5th October 2020. Written, signed consent is required of all trial participants. PRIME-RT will be performed according to the Research Governance Framework for Health and Community Care (Second Edition, 2016).
: Not applicable. No patient level information in this manuscript.
: Catherine R. Hanna, Sean M. O’Cathail, Janet S. Graham, Mark Saunders, Les Samuel, Mark Harrison, Lynsey Devlin, Joanne Edwards, Caroline A. Kelly, Liz-Anne Lewsley, Noori Maka, Paula Morrison, Louise Dinnett, Susan Dillon, Jacqueline Gourlay, Jonathan J. Platt : None. Fiona Thomson: Shareholder: MSD and AstraZeneca, Richard A Adams: Speakers fees/consultancy: Amgen, AZ, MSD, Merck Serono, Bayer. Research funding: MSD, AZ. The PRIME-RT trial is partly supported by Astra Zeneca.
